Advanced Search


Study ID Status Title Patient Level Data
114636 Completed A single-blind, non-randomized pharmacokinetic and safety study of single dose of GSK573719 and GSK573719 + GW642444 combination in healthy subjects and in subjects with severe renal impairment Study Listed on
114637 Completed An open-label, non-randomized, pharmacokinetic and safety study of single dose GSK573719 + GW643444 (VI) combination and repeat doses of GSK573719 in healthy subjects and in subjects with moderate hepatic impairment Study Listed on
114639 Completed A double blind randomised placebo controlled two way cross over study to determine the effect of GSK962040 on oesophageal function and gastric emptying in healthy male volunteers. Study Listed on
114643 Terminated A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission with GSK1605786A in Subjects with Moderately-to-Severely Active Crohn’s Disease
114644 Terminated An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects with Crohn’s Disease
114648 Completed A multi-centre, double blind, double dummy, randomised, controlled study to evaluate the efficacy and safety of TDF 300mg once daily (QD) versus adefovir dipivoxil (ADV) 10mg QD in Chinese subjects with CHB
114653 Completed A Phase II, Open-label, Multicenter, Randomized Study to Assess the Efficacy and Safety of GSK1120212 Compared with Docetaxel in 2nd Line Subjects with Targeted Mutations (KRAS, NRAS, BRAF, MEK1) in Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC Stage IV)
114655 Completed A Phase I, Single-Sequence, Placebo-Controlled, Single-Blind Study to Evaluate the Effect of Repeat Oral Dosing of GSK1120212 on Cardiac Repolarization in Subjects with Solid Tumors
114656 Completed An Open-label, Randomized, 2-treatment, 2-period, 2-way Crossover, Single-dose Study to Determine the Relative Bioavailability of the MEK inhibitor, Trametinib, in Subjects with Solid Tumor Malignancies
114660 Completed A randomised, double-blind, placebo-controlled, cross-over study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending oral doses of GSK2239633 in healthy male subjects. Study Listed on
114661 Completed A Randomized, Single-Blind, Placebo Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK1440115 after a Single Dose and 7 Days of Repeat Dosing in Healthy Volunteers
114671 Completed A Single Centre, Single Sequence, Open-Label, Repeat-Dose Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects
114673 Not yet recruiting A phase I/II, open label, escalating dose, pilot study to assess the effect, safety, tolerability and pharmacokinetics of multiple subcutaneous doses of PRO051 in patients with Duchenne muscular dystrophy
114674 Withdrawn BEL114674: A 2 year study of efficacy and safety of intravenous belimumab versus placebo in subjects with idiopathic membranous nephropathy
114677 Completed A Phase 3 Multicenter, Randomized, Double-Blind, Active And Vehicle-Controlled Study Of The Safety And Efficacy Of A Clindamycin / Benzoyl Peroxide Gel Versus Clindamycin Gel Versus Benzoyl Peroxide Gel Versus Vehicle Gel In Subjects With Acne Vulgaris Study Listed on
114678 Completed Prospective 2-Year Longitudinal Study to Assess for Miconazole Resistance in Candida spp. with Repeated Treatment Courses of 0.25% Miconazole Nitrate ointment in Neonates and Infants up to 1 Year of Age with Recurrent Moderate-Severe Diaper Dermatitis complicated by Cutaneous Candidiasis
114679 Completed A Phase 3B, Multicenter, Assessor-Blinded Study of the Tolerability of Clindamycin 1%-Tretinoin 0.025% Gel used in Conjunction with Benzoyl Peroxide 4% Wash in Subjects with Mild to Moderate Facial Acne Vulgaris
114681 Completed A Phase 3 Multicenter, Randomized, Double-Blind, Active And Vehicle-Controlled Study Of The Safety And Efficacy Of CT Gel in Subjects With Acne Vulgaris
114688 Terminated A randomised, double-blind, dose-finding, multicenter study of the safety, tolerability, and efficacy of GSK2251052 therapy compared to imipenem-cilastatin in the treatment of adult subjects with febrile complicated lower urinary tract infections and acute pyelonephritis
114689 Terminated A prospective, randomized, double-blind, multi-center, dose-ranging study of the safety, tolerability and efficacy of GSK2251052 in the treatment of complicated intra-abdominal infections in adults
114693 Completed Two part study to investigate pharmacokinetics (PK) & pharmacodynamics (PD) of SB-705498, TRPV1 antagonist, in cough. Part A: open label study in healthy subjects to determine exposure to SB-705498. Part B: double-blind, placebo controlled, cross over study to investigate effect of SB-705498 on capsaicin induced cough and 24 hour cough counts in cough patients Study Listed on
114694 Completed An Open-label, Randomized, Single Dose, Two-Period Crossover study to Determine the Bioavailability of a Fixed Dose Combination Capsule Formulation of Dutasteride and Tamsulosin Hydrochloride (0.5mg/0.2mg) Relative to Co-administration of Dutasteride 0.5mg capsules and Tamsulosin Hydrochloride 0.2mg Study Listed on
114695 Completed Immunogenicity and safety of GlaxoSmithKline Biologicals’ (pre-) pandemic influenza vaccine Prepandrix™ in Korean subjects aged 18 to 60 years old
114700 Completed Immunogenicity and safety study of GlaxoSmithKline Biologicals' HPV-16/18 L1 AS04 vaccine when administered according to alternative 2-dose schedules in 9 - 14 year old females Study Listed on
114703 Completed A randomized, open-label, 3-period crossover study in healthy subjects to determine the effect of particle size on the pharmacokinetics of single oral 100mg doses of GSK1278863A Study Listed on



For more information on this register please email

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party. is a database that provides summary protocol information for ongoing clinical trials. is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.